Windlas Biotech IPO GMP, Grey Market Premium & Kostak Rates Today

We employ 954 employees at our four state-of-the-art manufacturing facilities in Dehradun, Uttarakhand India. We also have a salesforce and distribution network spread across 14 states. We market our own manufactured authentic nutraceutical, pharmaceutical and ayurvedic products to serve the semi-urban and rural communities at affordable prices. “The registered name of the company is Windlas Biotech Limited (Formerly known as Windlas Biotech Private Limited).”

Innovation is at the core of our spirit at Windlas. We aim to deliver customized, innovative and complex generic products to our customers. Our R&D team work closely with customers or prospective customers, and provide innovative and cost efficient solutions tailored to meet specific customer requirements. When we work on a customer specific project then the customers also oversees the planning and execution of our projects. Our R&D team oversees the transfer of technology from lab scale to plant scale and prepares back-up strategies. Thereafter, we scale-up our operations from the R&D stage to large-scale manufacturing. We emphasize on maintaining consistency in the quality of our products as well as planning and executing projects in a timely manner.

We are constantly focused on improving efficiency of our operations and increasing the value of our research and manufacturing services to our clients. We are proud of our undeterred focus on quality and compliance assurance systems that provide authentic, efficacious and safe products to all patients consuming our products. Our dedication to quality can be seen from the fact that almost 40% of our staff workforce is in Quality Control / Quality Assurance functions.

•  IPO Grey Market Premium (Windlas Biotech IPO GMP) mention is valid for the specific date as mentioned in the header.
•  We are not buying and selling IPO forms on IPO Grey Market.
•  Kostak Rate is the premium one gets by selling his/her IPO application (in an off-market transaction) to someone else even before allotment or listing of the issue.
• Do not subscribe for IPO by just seeing premium Price as it may change anytime before listing. Subscribe only considering Fundamental of the companies.